| Literature DB >> 34729558 |
Matthew Gagne, Kizzmekia S Corbett, Barbara J Flynn, Kathryn E Foulds, Danielle A Wagner, Shayne F Andrew, John-Paul M Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T Nurmukhambetova, Meredith E Davis-Gardner, Laurent Pessaint, Kevin W Bock, Bianca M Nagata, Mahnaz Minai, Anne P Werner, Juan I Moliva, Courtney Tucker, Cynthia G Lorang, Bingchun Zhao, Elizabeth McCarthy, Anthony Cook, Alan Dodson, Prakriti Mudvari, Jesmine Roberts-Torres, Farida Laboune, Lingshu Wang, Adrienne Goode, Swagata Kar, Seyhan Boyoglu-Barnum, Eun Sung Yang, Wei Shi, Aurélie Ploquin, Nicole Doria-Rose, Andrea Carfi, John R Mascola, Eli A Boritz, Darin K Edwards, Hanne Andersen, Mark G Lewis, Mehul S Suthar, Barney S Graham, Mario Roederer, Ian N Moore, Martha C Nason, Nancy J Sullivan, Daniel C Douek, Robert A Seder.
Abstract
mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time; however, there are limited data on the impact of durability of immune responses on protection. We immunized rhesus macaques at weeks 0 and 4 and assessed immune responses over one year in blood, upper and lower airways. Serum neutralizing titers to Delta were 280 and 34 reciprocal ID 50 at weeks 6 (peak) and 48 (challenge), respectively. Antibody binding titers also decreased in bronchoalveolar lavage (BAL). Four days after challenge, virus was unculturable in BAL and subgenomic RNA declined ∼3-log 10 compared to control animals. In nasal swabs, sgRNA declined 1-log 10 and virus remained culturable. Anamnestic antibody responses (590-fold increase) but not T cell responses were detected in BAL by day 4 post-challenge. mRNA-1273-mediated protection in the lungs is durable but delayed and potentially dependent on anamnestic antibody responses. Rapid and sustained protection in upper and lower airways may eventually require a boost.Entities:
Year: 2021 PMID： 34729558 PMCID： PMC8562540 DOI： 10.1101/2021.10.23.465542
Source DB: PubMed Journal: bioRxiv